2 December 2021
NSW Health Minister, the Honourable Brad Hazzard, Launches SpeeDx New Facility
SYDNEY AUSTRALIA - December 1st, 2021, The NSW Minister for Health and Medical Research, the Honourable Brad Hazzard, attended the...
27 October 2021
SpeeDx Recognised as Australian Company of the Year
SYDNEY, AUSTRALIA - (October 27, 2021). SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have been awarded Australian...
6 October 2021
SARS-CoV-2 Variant Analysis Portfolio Further Expanded
SpeeDx have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation...
28 September 2021
SpeeDx announces investment in SynGenis
SpeeDx announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster internal capacity...
1 September 2021
SpeeDx included in new PHE National Microbiology Framework
SpeeDx has been included in the new Public Health England (PHE) National Microbiology Framework to supply Diagnostic goods and services...
17 August 2021
SARS-CoV-2 Variant Analysis Portfolio Expanded
SpeeDx have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the...
